Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity

In this week's episode we’ll discuss the safety and efficacy of decitabine in older patients with AML; learn how heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice, and discuss the outcomes of treatment with HLA-mismatched HSCT with TCRab/CD19 lymphocyte depletion or post-HSCT cyclophosphamide for inborn errors of immunity.

Featured Articles:

• Decitabine in older patients with AML: Quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase III trial 
• Heme induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice 
• Outcomes of HLA-mismatched HSCT with TCRab/CD19 depletion or post-HSCT cyclophosphamide for inborn errors or immunity 

What is Blood Podcast?

Stay up to date on the latest research and reviews for both clinical and basic hematology with Blood podcast, published weekly in conjunction with each issue of Blood. Additionally, Blood review series podcasts feature in depth discussion with authors of recently published review articles. Subscribe and never miss a new episode.